MedPath

Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies

Phase 2
Completed
Conditions
Metastasis
Cholangiocarcinoma
Hepatocellular Carcinoma
Interventions
Device: Separable cluster electrode (Octopus®)
Registration Number
NCT02683538
Lead Sponsor
Seoul National University Hospital
Brief Summary

The purpose of this study is to evaluate the clinical feasibility and short-term outcome of switching monopolar RFA using a separable cluster electrode in patients with primary and secondary liver malignancies.

Detailed Description

Radiofrequency ablation (RFA) is one of minimal invasive treatment methods and it has been showing comparable overall survival with surgery in early or small hepatocellular carcinomas (HCCs) and better cost-effectiveness. However, it is suffering from high local tumor progression (LTP) rate. To reduce LTP rate, creation of large ablative zone has been attempted in various strategies. A separable cluster electrode is a new type of RFA electrode. It consists of three individual applicators and the applicators can be incorporated as a single handle such as a cluster electrode, and can be separated as three electrodes, depending on operators' needs. It allows high flexibility to operators and the preclinical results were promising. Herein, we want to evaluate the clinical feasibility of the electrodes by observing major complication rates, technical success rate and 12-months LTP rate.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
196
Inclusion Criteria
  • Hepatic malignancies diagnosed on biopsy OR
  • Typical imaging features of hepatocellular carcinoma (HCC) on computed tomography (CT) or magnetic resonance imaging (MRI) according to AASLD guideline
  • Typical imaging feature of metastasis on CT or MRI AND
  • 1~5 tumors equal to or smaller than 5cm in the liver
  • no direct contact with or invasion into the hepatic hilar structures or inferior vena cava (IVC)
  • Eastern Cooperative Oncology Group performance status of 0
  • Patients who signed informed consent
Exclusion Criteria

Patients with any of followings are excluded.

  • Patients with uncontrolled coagulopathy
  • Patients with Child-Pugh classification C
  • Patients with tumor invasion in major portal vein or hepatic vein branch
  • Extrahepatic metastasis

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Separable cluster electrodeSeparable cluster electrode (Octopus®)radiofrequency ablation (RFA) using separable cluster electrode in switching monopolar mode.
Primary Outcome Measures
NameTimeMethod
Major complication rate after Radiofrequency ablation (RFA)30 days after RFA

Rates of major complication according to Society of Interventional Radiology (SIR) grading system, which refers to an event that leads to substantial morbidity and disability (SIR classification C-E).

Secondary Outcome Measures
NameTimeMethod
Technical success1 day after RFA

Technical success addresses that the tumor was treated according to protocol and completely covered by ablative zone on pre-RFA image and post-RFA image side-by-side comparison.

Local control rate12 months after RFA

Rate of local tumor progression after RFA

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath